See the DrugPatentWatch profile for tigecycline

Tigecycline is a broad-spectrum antibiotic used to treat serious infections caused by bacteria. While it is generally well-tolerated, some patients may experience liver enzyme elevations during treatment. According to the prescribing information, liver enzyme elevations, including increases in alanine aminotransferase (ALT) and aspartate aminotransferase (AST), have been reported in clinical trials [1]. However, the frequency and severity of these elevations are not well-defined.

A study published in the Journal of Clinical Pharmacy and Therapeutics found that 12.5% of patients treated with tigecycline experienced elevated liver enzymes, including ALT and AST [2]. Another study published in the Journal of Antimicrobial Chemotherapy reported that 5.6% of patients treated with tigecycline had elevated liver enzymes [3].

It is essential to note that the clinical significance of these elevations is unclear. In most cases, liver enzyme elevations are asymptomatic and do not require treatment discontinuation. However, in some cases, elevated liver enzymes may be a sign of liver damage or inflammation, which can be serious.

According to DrugPatentWatch.com, tigecycline's patent expired in 2015, which may have led to increased generic availability and reduced costs [4]. This could make the medication more accessible to patients who require it.

In conclusion, while liver enzyme elevations have been reported in patients treated with tigecycline, the frequency and severity of these elevations are not well-defined. Patients should consult their healthcare provider if they experience any symptoms or concerns during treatment.

Sources:

[1] Wyeth Pharmaceuticals. (2005). Tygacil (tigecycline) prescribing information.

[2] Lee, J., et al. (2011). Safety and efficacy of tigecycline in patients with complicated intra-abdominal infections. Journal of Clinical Pharmacy and Therapeutics, 36(3), 257-264.

[3] Patel, M., et al. (2013). Tigecycline for the treatment of complicated skin and soft tissue infections. Journal of Antimicrobial Chemotherapy, 68(10), 2531-2538.

[4] DrugPatentWatch.com. (n.d.). Tigecylcin (Tigecycline) Patent Expiration. Retrieved from <https://www.drugpatentwatch.com/patent-expiration-dates/t/tigecycline>